Explore the vast range of titles available.

In the following years the Fermilab Muon Campus will deliver highly polarized muon beams to the storage ring of the Muon g-2 Experiment. The Muon Campus contains a target section wherein secondaries are produced, the Delivery Ring which separates the muons from the rest of the beam and a straight section that transports them to the storage ring. Here, we report the first experimental results and experience gained from commissioning the Muon Campus, including the interaction of the proton beam with the target, the transport of secondary beam over long sections, the monitoring of muons from the available diagnostics and the development of techniques for measuring the beam optics. We present detailed comparisons between experimental data and simulation and discuss the similarities and differences observed.

A method has been developed for ab initio determination of crystallographic phases. This technique, called forced coalescence phasing (FCP), is implemented on a computer and uses an automated iterative procedure that combines real space filtering with numerically seeded Fourier transforms to solve the crystallographic phase problem. This approach is fundamentally different from that of traditional direct methods of phasing, which rely on structure invariant probabilistic phase relationships. In FCP, the process begins with an appropriate set of atoms randomly distributed throughout the unit cell. In subsequent cycles of the program, these atoms undergo continual rearrangements ultimately forming the correct molecular structure(s) consistent with the observed x-ray data. In each cycle, the molecular rearrangement is directed by an electron density (Fourier) map calculated using specially formulated numerical seed coefficients that, along with the phase angles for the map, are derived from the arrangement of atoms in the preceding cycle. The method has been tested using actual x-ray data from three organic compounds. For each data set, 100 separate phase determination trials were conducted, each trial beginning with a different set of randomly generated starting phases. Correct phase sets were successfully determined in all of the trials with most trials requiring fewer than 50 cycles of the FCP program. In addition to its effectiveness in small molecule phase determination, FCP offers unexplored potential in the application of real-space methods to ab initio phasing of proteins and other macromolecule structures.

The Fermilab Muon Campus will host the Muon g-2 experiment - a world class experiment dedicated to the search for signals of new physics. Strict demands are placed on beam diagnostics in order to ensure delivery of high quality beams to the storage ring with minimal losses. In this study, we briefly describe the available secondary beam diagnostics for the Fermilab Muon Campus. Then, with the aid of numerical simulations we detail their interaction with the secondary beam. Finally, we compare our results against theoretical findings.

A new measurement of the magnetic anomaly \\(a_{\\mu}\\) of the positive muon is presented based on data taken from 2020 to 2023 by the Muon \\(g-2\\) Experiment at Fermi National Accelerator Laboratory (FNAL). This dataset contains over 2.5 times the total statistics of our previous results. From the ratio of the precession frequencies for muons and protons in our storage ring magnetic field, together with precisely known ratios of fundamental constants, we determine \\(a_{\\mu} = 116\\,592\\,0710(162) \\times 10^{-12}\\) (139 ppb) for the new datasets, and \\(a_{\\mu} = 116\\,592\\,0705(148) \\times 10^{-12}\\) (127 ppb) when combined with our previous results. The new experimental world average, dominated by the measurements at FNAL, is \\(a_{\\mu}(\\text{exp}) =116\\,592\\,0715(145) \\times 10^{-12}\\) (124 ppb). The measurements at FNAL have improved the precision on the world average by over a factor of four.

We present details on a new measurement of the muon magnetic anomaly, \\(a_\\mu = (g_\\mu -2)/2\\). The result is based on positive muon data taken at Fermilab's Muon Campus during the 2019 and 2020 accelerator runs. The measurement uses \\(3.1\\) GeV\\(/c\\) polarized muons stored in a \\(7.1\\)-m-radius storage ring with a \\(1.45\\) T uniform magnetic field. The value of \\( a_{\\mu}\\) is determined from the measured difference between the muon spin precession frequency and its cyclotron frequency. This difference is normalized to the strength of the magnetic field, measured using Nuclear Magnetic Resonance (NMR). The ratio is then corrected for small contributions from beam motion, beam dispersion, and transient magnetic fields. We measure \\(a_\\mu = 116 592 057 (25) \\times 10^{-11}\\) (0.21 ppm). This is the world's most precise measurement of this quantity and represents a factor of \\(2.2\\) improvement over our previous result based on the 2018 dataset. In combination, the two datasets yield \\(a_\\mu(\\text{FNAL}) = 116 592 055 (24) \\times 10^{-11}\\) (0.20 ppm). Combining this with the measurements from Brookhaven National Laboratory for both positive and negative muons, the new world average is \\(a_\\mu\\)(exp) \\( = 116 592 059 (22) \\times 10^{-11}\\) (0.19 ppm).

The Muon (g-2) Experiment, E989 at Fermilab, will measure the muon anomalous magnetic moment a factor-of-four more precisely than was done in E821 at the Brookhaven National Laboratory AGS. The E821 result appears to be greater than the Standard-Model prediction by more than three standard deviations. When combined with expected improvement in the Standard-Model hadronic contributions, E989 should be able to determine definitively whether or not the E821 result is evidence for physics beyond the Standard Model. After a review of the physics motivation and the basic technique, which will use the muon storage ring built at BNL and now relocated to Fermilab, the design of the new experiment is presented. This document was created in partial fulfillment of the requirements necessary to obtain DOE CD-2/3 approval.

Mu2e at Fermilab will search for charged lepton flavor violation via the coherent conversion process mu- N --> e- N with a sensitivity approximately four orders of magnitude better than the current world's best limits for this process. The experiment's sensitivity offers discovery potential over a wide array of new physics models and probes mass scales well beyond the reach of the LHC. We describe herein the conceptual design of the proposed Mu2e experiment. This document was created in partial fulfillment of the requirements necessary to obtain DOE CD-1 approval, which was granted July 11, 2012.

To compare the effectiveness and safety of prescribing ibuprofen and oxycodone for at-home management of children's fracture pain. A prospective observational cohort was conducted at the Stollery Children's Hospital pediatric emergency department (June 2010-July 2014). Children aged 4-16 years with an isolated fracture discharged home with advice to use either ibuprofen or oxycodone were recruited. A cohort of 329 children (n = 217 ibuprofen, n = 112 oxycodone) were included. Mean age was 11.1 years (SD 3.5); 68% (223/329) were male. Fracture distribution included 80.5% (264/329) upper limb with 34.3% (113/329) requiring fracture reduction. The mean reduction in Faces Pain Score-Revised score (maximum pain-post-treatment pain) for Day 1 was 3.6 (SD 1.9) (ibuprofen) and 3.8 (SD 2.1) (oxycodone) (p = 0.50); Day 2 was 3.6 (SD 1.8) (ibuprofen) and 3.7 (SD 1.6) (oxycodone) (p = 0.56); Day 3 was 3.7 (SD 1.7) (ibuprofen) and 3.3 (SD 1.7) (oxycodone) (p = 0.24). Children prescribed ibuprofen (51.2%, 109/213) experienced less adverse events compared to those prescribed oxycodone (70.5% 79/112) on Day 1 (p = 0.001). Children prescribed ibuprofen (71.8%, 150/209) had their function (eat, play, school, sleep) affected less than those prescribed oxycodone (83.0%, 93/112) (p = 0.03) on Day 1. Children prescribed ibuprofen or oxycodone experienced similar analgesic effectiveness for at-home fracture pain. Oxycodone prescribing was associated with more adverse events and negatively impacted function. Oxycodone use does not appear to confer any benefit over ibuprofen for pain relief and has a negative adverse effect profile. Ibuprofen appears to be a safe option for fracture-related pain.

In adolescents and young adults, suicide is the second leading cause of death [1]. Suicide is a growing public health concern which requires ongoing effort to identify patients with suicidal ideation early to provide necessary resources and interventions to prevent negative outcomes.Financial support This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.Author contributions Michelle L Pickett: Conceptualization, methodology, formal analysis, writing-original draft, visualization; Callie Krentz: Data curation, formal analysis, writing-original draft; Mark Nimmer: Data curation, formal analysis, writing-review and editing; Ashley Servi: conceptualization, writing-review and editing; Anna Schmitz: Methodology, writing-review and editing; Amy L Drendel: Conceptualization, writing-review and editing, supervision.Presentation This was presented as a poster presentation at the Pediatric Academic Societies annual meeting in Baltimore, Maryland in April 2019.Declaration of Competing Interest None. Screened (N = 1577) Not screened (N = 484) p-Value Gender, female 851 (54.0) 255 (52.7) 0.622 Age 0.279 11–14 years old 862 (54.7) 251 (51.9) 15–18 years old 715 (45.3) 233 (48.1) Chief complaint 0.023 Non-psychiatric 1494 (94.7) 445 (91.9) Psychiatrica 83 (5.3) 39 (8.1) Triage level <0.001 1 4 (0.25) 14 (2.9) 2 193 (12.2) 121 (25.0) 3 781 (49.5) 208 (43.0) 4 516 (32.7) 108 (22.3) 5 83 (5.3) 21 (4.3) Unknown 0 (0.0) 12 (2.5) Disposition <0.001 Discharged 1373 (87.1) 332 (68.6) Admitted 178 (11.3) 114 (23.6) AMA/Eloped/LWBSb 5 (0.32) 15 (3.1) Transferred (psychiatric) 17 (1.1) 18 (3.7) Transferred (non-psychiatric) 4 (0.26) 3 (0.61) Unknown 0 (0.0) 2 (0.40) Table 2 Comparison of screened and not screened patient encounters during the post-implementation period, N (%).

We report on a case in which cell-free fetal DNA was positive for trisomy 13 most likely due to confined placental mosaicism. Cell-free fetal DNA testing analyzes DNA derived from placental trophoblast cells and can lead to incorrect results that are not representative of the fetus. We sought to confirm commercial cell-free fetal DNA testing results by chorionic villus sampling and amniocentesis. These results were followed up by postnatal chromosome analysis of cord blood and placental tissue. First-trimester cell-free fetal DNA test results were positive for trisomy 13. Cytogenetic analysis of chorionic villus sampling yielded a mosaic karyotype of 47,XY,+13[10]/46,XY[12]. G-banded analysis of amniotic fluid was normal, 46,XY. Postnatal cytogenetic analysis of cord blood was normal. Karyotyping of tissues from four quadrants of the placenta demonstrated mosaicism for trisomy 13 in two of the quadrants and a normal karyotype in the other two. Our case illustrates several important aspects of this new testing methodology: that cell-free fetal DNA may not be representative of the fetal karyotype; that follow-up with diagnostic testing of chorionic villus sampling and/or amniotic fluid for abnormal test results should be performed; and that pretest counseling regarding the full benefits, limitations, and possible testing outcomes of cell-free fetal DNA screening is important. Genet Med15 9, 729–732.